Skip to main content

Market Overview

Why Tricida's Stock Is Trading Lower Today

Why Tricida's Stock Is Trading Lower Today

Tricida (NASDAQ: TCDA) shares are trading lower on Monday after the company received a Complete Response Letter from the FDA for its New Drug Application for Veverimer.

Tricida is a late-stage pharmaceutical company. It is focused on the development and commercialization of its drug candidate, veverimer (TRC101), a non-absorbed, orally-administered polymer designed to treat metabolic acidosis by binding and removing acid from the gastrointestinal, or GI, tract. The primary area of focus is to slow the progression of chronic kidney disease through the treatment of metabolic acidosis.

Tricida shares were trading down 23.56% at $10.12 on Monday during the time of publication. The stock has a 52-week high of $44.30 and a 52-week low of $9.56.


Related Articles (TCDA)

View Comments and Join the Discussion!

Posted-In: why it's movingNews FDA

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at